Healthcare Industry News: S.A.
News Release - August 17, 2007
EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
LYON, France, Aug. 17 (HSMN NewsFeed) -- EDAP TMS S.A. (NaS.A.: EDAP ), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of proS.A.e cancer, is currently conducting clinical investigations in France under an approved clinical trial combining the company'S.A.latherm-HIFU device with chemotherapy using docetaxel.The study iS.A.primary treatment therapy program for men suffering from clinically localized but aggressive high risk proS.A.e cancer typically classified as S.A.e T2c. The study began in late 2006 and will enroll a total of 30 men, of which more than 10 have already been treated.
"Combination therapy is well documented aS.A.treatment protocol for men suffering more aggressive proS.A.e cancers," said Dr. Albert Gelet, Edouard Herriot Hospital, Lyon. "Ablatherm-HIFU iS.A.proven effective treatment for localized proS.A.e cancer already with strong clinical support. This study aims to evaluate its use under an additional dedicated protocol for men in the T2c cancer S.A.e where the tumorS.A.e known to be more aggressive, creating a higher risk of relapse if the patient is treated with only a localized therapy. It was demonstrated in pre-clinical studies that HIFU improves chemotherapy drug efficacy in the area around burned tissues."
Under the approved protocol by French Ethical Committee, patientS.A.e administered a dose of docetaxel 30 minutes prior to a S.A.dard primary indication HIFU session lasting an average of two hours. The Ablatherm-HIFU ablates the proS.A.e tissue according to conventional procedureS.A.d protocols. All treatmentS.A.e administered at Edouard Herriot Hospital in Lyon, France.
"EDAP haS.A.strong scientific and clinical base underlying the Ablatherm-HIFU, with conS.A.t work to enhance and extend the capabilities of the device," said Pr John Rewcastle, Medical Director for EDAP. "With already well documented specialized protocols for primary therapy, HIFU retreatment and salvage therapy following radiation failure, EDAP offers patientS.A.d physicianS.A.S.A.istical consistency of outcomes unmatched by traditional therapies. We intend to document the strength of Ablatherm-HIFU not only aS.A.S.A.dalone focal treatment, but also in combination with other choices, giving doctorS.A. enhanced arsenal in the fight against proS.A.e cancer while preserving patient quality of life."
"EDAP continues to expand its market opportunity through rigorouS.A.d consistent clinical evaluation of the Ablatherm-HIFU system," said Marc Oczachowski, CEO of EDAP. "This test demonstrates the opportunity for Ablatherm to work in concert with other therapies for higher risk patients, expanding the potential population for whom Ablatherm-HIFU may be a solution."
About EDAP TMS S.A.
EDAP TMS S.A. developS.A.d marketS.A.latherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized proS.A.e cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized proS.A.e cancer (S.A.es T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. The company iS.A.so developing this technology for the potential treatment of certain other types of tumors. EDAP TMS S.A. also produceS.A.d commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).
For more information on the Company, contact Magnolia Investor RelationS.A. (972) 801-4900, the Corporate Investor Relations Dept at +33 (0)4 78 26 40 46 or see the Company's Web siteS.A. http://www.edap-tms.com and http://www.hifu-planet.com.
To sign up for alerts please visit: http://www.b2i.us/irpasS.A.p?BzID=1053&to=ea&s=0
In addition to historical information, this press release contains forward-looking S.A.ements that involve riskS.A.d uncertainties. These include S.A.ements regarding the Company's growth and expansion plans. Such S.A.ementS.A.e based on management's current expectationS.A.d are subject to a number of uncertaintieS.A.d risks that could cause actual results to differ materially from those described in these forward-looking S.A.ements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the SecuritieS.A.d Exchange Commission. Ablatherm-HIFU treatment is in clinical trials but not yet FDA approved or marketed in the United S.A.es.
Source: EDAP TMS
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!